Therapy-related acute leukaemia with Mitoxantrone: What is the risk and can we minimise it?

Multiple Sclerosis

Volumn 15, Issue 4, 2009, Pages 505-508

  Ellis, Richard ^a   Boggild, M ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Disease modifying therapies; Mitoxantrone; Multiple sclerosis

Indexed keywords

MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; CASE STUDY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROMYELOCYTIC LEUKEMIA; RISK REDUCTION;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 63449128972     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508100967     Document Type: Article

References (15)

1. Compston, A, Coles, A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
2. Fox, E. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther 2006; 28: 461-474.
3. Gonsette, RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996; 1: 329-332.
4. Fox, EJ. Mechanism of action of mitoxantrone. Neurology 2004; 63(Suppl. 6): S15-S18.
5. Edan, G, Morrissey, S, Le Page, E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35-39.
6. Ghalie, RG, Edan, G, Laurent, M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in MS. Neurology 2002; 59: 909-913.
7. Le Page, E, Leray, E, Taurin, G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79(1): 52-56.
8. Cavalla, P, Rovei, V, Masera, S, et al. Fertility in patients with multiple sclerosis: Current knowledge and future perspectives. Neurol Sci 2006; 27: 231-239.
9. Mistry, AR, Felix, CA, Whitmarsh, BA, et al. DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukaemia. N Engl J Med 2005; 352: 1529-1538.
10. Vickers, M, Jackson, G, Taylor, P. The incidence of acute Promyelocytic leukaemia appears constant over most of the human lifespan, implying only one rate limiting mutation. Leukaemia 2000; 14: 722-726.
11. Merck. Acute Leukemia: Leukemias: Merck Manual Profession. Merck and Co., Inc.; c1995-2008. Available from http://www.merck.com/mmpe/sec11/ ch142/ch142b.html [updated Nov 2005; cited 22 July 2008].
12. Heesen, C, Bruegmann, M, Gbdamosi, J, Koch, E, Mönch, A, Buhmann, C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003; 9: 213-214.
13. Cocco, E, Marchi, P, Sardu, C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 975-980.
14. Ramtahal, J, Jacob, A, Das, K, Boggild, M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006; 253: 1160-1164.
15. Vollmer, T, Panitch, H, Bar-Or, A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14(5): 663-670.